A Two-Part Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Repeat Doses of Inhaled ETD001 in People With Cystic Fibrosis
- First Posted Date
- 2024-06-27
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Enterprise Therapeutics Ltd
- Target Recruit Count
- 40
- Registration Number
- NCT06478706
- Locations
- 🇫🇷
Hospices Civils de Lyon, Lyon, France
🇫🇷CHU de Montpellier, Montpellier, France
🇫🇷Hôpital Cochin, Paris, France
A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled ETD001 in Healthy Subjects
Phase 1
Completed
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: ETD001 multiple twice daily dosesDrug: ETD001 single doseDrug: Placebo single doseDrug: Placebo multiple twice daily dosesDrug: ETD001 multiple once daily dosesDrug: Placebo multiple once daily doses
- First Posted Date
- 2021-06-15
- Last Posted Date
- 2022-03-24
- Lead Sponsor
- Enterprise Therapeutics Ltd
- Target Recruit Count
- 98
- Registration Number
- NCT04926701
- Locations
- 🇬🇧
Hammersmith Medicines Research, London, United Kingdom
A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled ETD002 in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: ETD002 - 14 day repeat doseDrug: ETD002 - single doseDrug: ETD002 - 7 day repeat doseDrug: Placebo - single doseDrug: Placebo - 14 day repeat doseDrug: Placebo - 7 day repeat dose
- First Posted Date
- 2020-07-28
- Last Posted Date
- 2021-05-21
- Lead Sponsor
- Enterprise Therapeutics Ltd
- Target Recruit Count
- 80
- Registration Number
- NCT04488705
- Locations
- 🇬🇧
Hammersmith Medicines Research, London, United Kingdom